JP2018530581A5 - - Google Patents

Download PDF

Info

Publication number
JP2018530581A5
JP2018530581A5 JP2018519274A JP2018519274A JP2018530581A5 JP 2018530581 A5 JP2018530581 A5 JP 2018530581A5 JP 2018519274 A JP2018519274 A JP 2018519274A JP 2018519274 A JP2018519274 A JP 2018519274A JP 2018530581 A5 JP2018530581 A5 JP 2018530581A5
Authority
JP
Japan
Prior art keywords
dmso
soluble
dissolved
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018519274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018530581A (ja
JP6957455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/056528 external-priority patent/WO2017066240A1/en
Publication of JP2018530581A publication Critical patent/JP2018530581A/ja
Publication of JP2018530581A5 publication Critical patent/JP2018530581A5/ja
Priority to JP2021164809A priority Critical patent/JP2022008902A/ja
Application granted granted Critical
Publication of JP6957455B2 publication Critical patent/JP6957455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018519274A 2015-10-14 2016-10-12 ベータ細胞の複製及び/または生存の亢進 Active JP6957455B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021164809A JP2022008902A (ja) 2015-10-14 2021-10-06 ベータ細胞の複製及び/または生存の亢進

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562241566P 2015-10-14 2015-10-14
US62/241,566 2015-10-14
US201662279908P 2016-01-18 2016-01-18
US62/279,908 2016-01-18
PCT/US2016/056528 WO2017066240A1 (en) 2015-10-14 2016-10-12 Enhancing beta cell replication and/or survival

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021164809A Division JP2022008902A (ja) 2015-10-14 2021-10-06 ベータ細胞の複製及び/または生存の亢進

Publications (3)

Publication Number Publication Date
JP2018530581A JP2018530581A (ja) 2018-10-18
JP2018530581A5 true JP2018530581A5 (cg-RX-API-DMAC7.html) 2019-05-09
JP6957455B2 JP6957455B2 (ja) 2021-11-02

Family

ID=58518528

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018519274A Active JP6957455B2 (ja) 2015-10-14 2016-10-12 ベータ細胞の複製及び/または生存の亢進
JP2021164809A Pending JP2022008902A (ja) 2015-10-14 2021-10-06 ベータ細胞の複製及び/または生存の亢進

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021164809A Pending JP2022008902A (ja) 2015-10-14 2021-10-06 ベータ細胞の複製及び/または生存の亢進

Country Status (7)

Country Link
US (1) US20180235916A1 (cg-RX-API-DMAC7.html)
EP (1) EP3362069A4 (cg-RX-API-DMAC7.html)
JP (2) JP6957455B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180054796A (cg-RX-API-DMAC7.html)
CN (1) CN108697712A (cg-RX-API-DMAC7.html)
AU (2) AU2016338916B2 (cg-RX-API-DMAC7.html)
WO (1) WO2017066240A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014018110B1 (pt) 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
IL294306B2 (en) 2012-08-21 2024-01-01 Sage Therapeutics Inc Methods of treating epilepsy or status epilepticus
US20150313915A1 (en) 2012-11-30 2015-11-05 The Regents Of The University Of California Anticonvulsant activity of steroids
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
US20200306265A1 (en) 2016-03-08 2020-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3642206A4 (en) * 2017-06-23 2021-04-07 The Regents of The University of California INCREASED GABA ABILITY TO MODULATE IMMUNE REACTIONS
WO2020081886A1 (en) * 2018-10-18 2020-04-23 The Regents Of The University Of California Homotaurine for treatment of inflammation-related disorders
US20230028307A1 (en) * 2020-01-10 2023-01-26 Equilibre Biopharmaceuticals Bv Treatment of neurological disorders with avermectins
US20250375429A1 (en) * 2024-05-29 2025-12-11 Smarter Not Harder, Inc. Obligate pairing of orthosteric and non-orthosteric gaba ligands in pharmaceutical formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3503300A (en) * 1999-02-24 2000-09-14 Regents Of The University Of California, The Gaba receptors mediate inhibition of t cell responses
DK2621282T3 (da) * 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2014048788A1 (en) * 2012-09-27 2014-04-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for producing a population of pancreatic beta-cells
US10472324B2 (en) * 2014-03-18 2019-11-12 Algiax Pharmaceuticals Gmbh 2-cyano-3-cyclopropyl-3-hydroxy-N-aryl-thioacrylamide derivatives

Similar Documents

Publication Publication Date Title
JP2018530581A5 (cg-RX-API-DMAC7.html)
HUE054103T2 (hu) Izokinolin-3-il-karboxamidok, ezek elõállítása és alkalmazása
JP2017514877A5 (cg-RX-API-DMAC7.html)
JP2014237817A5 (cg-RX-API-DMAC7.html)
JP2016196495A5 (cg-RX-API-DMAC7.html)
JP2016028081A5 (cg-RX-API-DMAC7.html)
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
DK3297637T3 (da) Benzen-1,3,5-tricarboxamidderivater og anvendelser deraf
JP2017519346A5 (cg-RX-API-DMAC7.html)
JP2016503708A5 (cg-RX-API-DMAC7.html)
FIC20250026I1 (fi) Niraparibi tai sen farmaseuttisesti hyväksytty suola etenkin niraparibitosylaatti etenkin niraparibitosylaattimonohydraatti, valinnaisesti yhdessä abirateronin ja erityisesti abirateroniasetaatin kanssa.
HUE054037T2 (hu) CD71 elleni, aktiválható antitest hatóanyag konjugátumok és eljárások alkalmazásukra
SG11201801534RA (en) 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof
DK3612579T3 (da) Pultrudat, fremstilling og anvendelse heraf
MX2017006953A (es) Medicamentos para disminuir la evolucion de la enfermedad de parkinson.
JP2015173751A5 (cg-RX-API-DMAC7.html)
HUE070649T2 (hu) Benzimidazol-származékok és felhasználásuk
TWI561508B (en) Onium salt, chemically amplified positive resist composition, and patterning process
JP2016540019A5 (cg-RX-API-DMAC7.html)
HUE049374T2 (hu) 3-(karboxietil)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-dekán származékok
LT3402785T (lt) 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai
JP2015016294A5 (cg-RX-API-DMAC7.html)
DK3604303T3 (da) Hidtil ukendt pyrrolopyridinderivat, fremgangsmåde til fremstilling heraf og anvendelse deraf
JP2017149782A5 (cg-RX-API-DMAC7.html)
JP2017197541A5 (cg-RX-API-DMAC7.html)